Evidence map›Paper›PMID 42846337›Full record

ArticleFrontiers in immunology2026

Pretreatment CT radiomics for prediction of pathological complete response after neoadjuvant chemoimmunotherapy in NSCLC: a multicenter study incorporating habitat analysis.

Sunyi Zheng, Shuyuan Huang, Jiahui Zhang, Xiaomeng Yang, PengChun Ye, Weiping Wang, Wenhua Li, Houpu Liu, Chunlin Zhang, Guoqing Liao and 4 more

Abstract readMulticenter Study
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Sunyi Zheng *Department of Radiology, Medical Artificial General Intelligence for Computation (MAGIC) Lab, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Shuyuan Huang *Department of Radiology, Medical Artificial General Intelligence for Computation (MAGIC) Lab, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Jiahui Zhang *Department of Lung Cancer, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center of Cancer, Lung Cancer Center, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Xiaomeng YangDepartment of Radiology, Medical Artificial General Intelligence for Computation (MAGIC) Lab, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
PengChun YeDepartment of Radiology, Medical Artificial General Intelligence for Computation (MAGIC) Lab, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Weiping WangAcademy of Medical Engineering and Translational Medicine, Tianjin University, Tianjin, China.
Wenhua LiDepartment of Radiology, Ordos Central Hospital, Ordos, China.
Houpu LiuDepartment of Radiology, Medical Artificial General Intelligence for Computation (MAGIC) Lab, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Chunlin ZhangDepartment of Radiology, Medical Artificial General Intelligence for Computation (MAGIC) Lab, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Guoqing LiaoDepartment of Thoracic Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China.
Haiyu ZhouDepartment of Thoracic Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China.
Jing WangSchool of Public Health, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Xiaonan CuiDepartment of Radiology, Medical Artificial General Intelligence for Computation (MAGIC) Lab, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Dongsheng YueDepartment of Lung Cancer, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center of Cancer, Lung Cancer Center, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Pathological complete response (pCR) after neoadjuvant chemoimmunotherapy (NACI) varies among patients with non-small cell lung cancer (NSCLC). This study aimed to quantify intratumoral heterogeneity using habitat analysis and to develop a pretreatment model for predicting pCR. Methods: In this retrospective multicenter study, 287 patients with NSCLC who received NACI followed by surgery were included. Patients were randomly divided into a training cohort (n = 147) and an internal validation cohort (n = 63), with an independent external test cohort (n = 77). K-means clustering was used to partition tumors into three habitat subregions based on entropy. Radiomics features were extracted from pretreatment CT images at the whole-tumor and habitat levels. Whole-tumor, habitat-based, and combined models were developed to predict pCR. Model performance was evaluated using area under the curve (AUC) analysis, and model interpretability was assessed using Shapley Additive exPlanations (SHAP). Results: The habitat-based model showed acceptable predictive performance across the training, internal validation, and external test cohorts, with AUCs of 0.74, 0.71, and 0.67, respectively, and showed higher AUCs compared with the whole-tumor radiomics model, which achieved AUCs of 0.72, 0.68, and 0.65. The combined model achieved performance comparable to the habitat-based model. SHAP analysis suggested that, among the habitat-derived features, the most influential predictive features were primarily associated with the high-entropy habitat subregion. Conclusion: The habitat-based model shows potential performance for predicting pCR, and features from a high-entropy habitat subregion may provide complementary imaging information for preoperative assessment of treatment response.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsNeoadjuvant TherapyTomography, X-Ray ComputedAgedFemaleHumansImmunotherapyMaleMiddle AgedPathologic Complete ResponseRadiomicsRetrospective StudiesTreatment Outcomehabitatneoadjuvant chemoimmunotherapynon-small cell lung cancerpathologic complete responseradiomics

Identifiers

PMID42846337
PMCPMC13642639

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.